82 of 203 patients with malignant melanoma and other skin diseases suitable for dncb-immunotherapy were re-exposed to standard test substances , chloramphenicol , and another four p-nitrocompounds similar to dncb by epicutaneous patch tests 6-15 months after primary sensitization with dncb .
C0025202
malignant melanoma
C0037274
skin diseases